Grupo Ferrer Internacional, S.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grupo Ferrer Internacional, S.A.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
Olema launched this year’s 75th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
Gene therapy shows promise in treating movement disorders in 4 patients, matching longer-term results from rivals Neurocrine Biosciences and Voyager Therapeutics.
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.
- In Vitro Diagnostics
- Medical Devices
- Drug Delivery
- Generic Drugs
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Other Names / Subsidiaries
- Addicere Therapeutics, Inc.
- Alexza Pharmaceuticals, Inc.